Supporting evidence
Insulin therapy × HbA1c
- Authoritative support
- 4
- Available studies
- 4
- Unavailable support
- 0
Available supporting studies
Study 1 · Included
Adding sitagliptin to insulin improves glycemic control in type 2 diabetes
Rct
- Comparison
- Patients received sitagliptin added to their existing insulin treatment. · Patients continued their previous insulin treatment without any additional medication.
- Duration / follow-up
- 24 weeks
Relevant effects
Mean difference
0.9 · 0.01
Mean difference
0 · 0.32
Study 2 · Included
QCC Model Enhances Diabetes Management
Rct
- Comparison
- Patients received individualised nutrition and insulin pump therapy supported by continuous glucose monitoring and the QCC nursing model. · Patients received standard care.
- Duration / follow-up
- 99 weeks
Relevant effect
Absolute change
0.5 · 0.05
Study 3 · Included
Semaglutide with Insulin Improves Diabetes Control and Kidney Health
Rct
- Comparison
- Patients received Semaglutide combined with insulin therapy. · Patients received conventional insulin therapy.
- Duration / follow-up
- Short term
Relevant effect
Percent change
1.66 · 0.001
Study 4 · Included
Vildagliptin improves glycemic control in type 2 diabetes patients on insulin
Rct
- Comparison
- Patients receiving vildagliptin treatment demonstrated significant reductions in HbA1c and GA levels. · Patients who only had their insulin doses adjusted without adding vildagliptin.
- Duration / follow-up
- 2 weeks
Relevant effect
Mean difference
0.71 · 0.001